{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T14:32:07Z","timestamp":1774103527501,"version":"3.50.1"},"reference-count":96,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T00:00:00Z","timestamp":1589760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["Grant ANRS-2019-1"],"award-info":[{"award-number":["Grant ANRS-2019-1"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0233084","type":"journal-article","created":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T17:50:08Z","timestamp":1589824208000},"page":"e0233084","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Serum and cervicovaginal IgG immune responses against \u03b17 and \u03b19 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0888-6251","authenticated-orcid":true,"given":"Ralph-Sydney","family":"Mboumba Bouassa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"P\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cam\u00e9lia","family":"Gubavu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Prazuck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad-Ali","family":"Jenabian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Veyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Meye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Touz\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"B\u00e9lec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,5,18]]},"reference":[{"issue":"5","key":"pone.0233084.ref001","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1525-1438.2005.00246.x","article-title":"Human papillomavirus infection: biology, epidemiology, and prevention","volume":"15","author":"ME Scheurer","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl 3","key":"pone.0233084.ref002","first-page":"S3\/11","article-title":"Chapter 2: The burden of HPV-related cancers","volume":"24","author":"DM Parkin","year":"2006","journal-title":"Vaccine"},{"issue":"5","key":"pone.0233084.ref003","doi-asserted-by":"crossref","first-page":"e0197845","DOI":"10.1371\/journal.pone.0197845","article-title":"Unusual and unique distribution of anal high-risk human papillomavirus (HR-HPV) among men who have sex with men living in the Central African Republic","volume":"13","author":"RS Mboumba Bouassa","year":"2018","journal-title":"PLoS One"},{"issue":"4","key":"pone.0233084.ref004","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens\u2014Part B: biological agents","volume":"10","author":"V Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"issue":"11","key":"pone.0233084.ref005","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"S de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"pone.0233084.ref006","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","article-title":"Classification of papillomaviruses","volume":"324","author":"EM de Villiers","year":"2004","journal-title":"Virology"},{"issue":"Suppl 5","key":"pone.0233084.ref007","doi-asserted-by":"crossref","first-page":"F32","DOI":"10.1016\/j.vaccine.2012.07.092","article-title":"The burden of human papillomavirus infections and related diseases in sub-saharan Africa","volume":"31","author":"H de Vuyst","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"pone.0233084.ref008","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"J Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"pone.0233084.ref009","unstructured":"World health Organization, 2015. Projections of mortality and causes of death, 2015 and 2030. (Last accessed September 2019). http:\/\/www.who.int\/healthinfo\/global_burden_disease\/projections\/en\/."},{"issue":"6","key":"pone.0233084.ref010","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/14787210.2017.1322902","article-title":"Cervical cancer in sub-Saharan Africa: a preventable noncommunicable disease","volume":"15","author":"RS Mboumba Bouassa","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"pone.0233084.ref011","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2017.04.004","article-title":"HPV vaccines\u2014A review of the first decade","volume":"146","author":"DM Harper","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"32 Pt A","key":"pone.0233084.ref012","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1016\/j.vaccine.2017.11.089","article-title":"Immunogenicity of HPV prophylactic vaccines: Serology assays and their use in HPV vaccine evaluation and development","volume":"36","author":"LA Pinto","year":"2018","journal-title":"Vaccine"},{"issue":"6","key":"pone.0233084.ref013","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1080\/21645515.2015.1108500","article-title":"Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancer","volume":"12","author":"R Luckett","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"pone.0233084.ref014","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pvr.2017.12.004","article-title":"Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women","volume":"5","author":"\u00c1M Ruiz-Sternberg","year":"2018","journal-title":"Papillomavirus Res"},{"issue":"6","key":"pone.0233084.ref015","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.vaccine.2018.12.030","article-title":"Safety of a quadrivalent human papillomavirus vaccine in a Phase 3, randomized, double-blind, placebo-controlled clinical trial among Chinese women during 90\u202fmonths of follow-up","volume":"37","author":"W Chen","year":"2019","journal-title":"Vaccine"},{"issue":"4","key":"pone.0233084.ref016","doi-asserted-by":"crossref","first-page":"pky045","DOI":"10.1093\/jncics\/pky045","article-title":"Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6\/11\/16\/18\/31\/33\/45\/52 and 58","volume":"2","author":"S de Sanjos\u00e9","year":"2019","journal-title":"JNCI Cancer Spectr"},{"key":"pone.0233084.ref017","article-title":"A systematic review of immunogenicity, clinical efficacy and safety of human papillomavirus vaccines in people living with the human immunodeficiency virus","author":"EJ Mavundza","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"pone.0233084.ref018","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2147\/IDR.S178381","article-title":"Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus","volume":"12","author":"ZQ Toh","year":"2019","journal-title":"Infect Drug Resist"},{"issue":"19","key":"pone.0233084.ref019","first-page":"241","article-title":"Human papillomavirus vaccines: WHO position paper, May 2017 \/ Vaccins contre les papillomavirus humains: note de synth\u00e8se de l\u2019OMS, mai 2017","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Weekly Epidemiological Record = Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire"},{"issue":"2","key":"pone.0233084.ref020","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrclinonc.2015.146","article-title":"HPV-FASTER: broadening the scope for prevention of HPV-related cancer","volume":"13","author":"FX Bosch","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"pone.0233084.ref021","doi-asserted-by":"crossref","first-page":"612","DOI":"10.21149\/10171","article-title":"HPV-FASTER: Combined strategies of HPV vaccination and HPV screening towards a one visit for cervical cancer preventive campaigns","volume":"60","author":"FX Bosch","year":"2018","journal-title":"Salud Publica Mex"},{"key":"pone.0233084.ref022","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pvr.2019.04.010","article-title":"Opportunities to improve immune-based prevention of HPV-associated cancers","volume":"7","author":"PL Stern","year":"2019","journal-title":"Papillomavirus Res"},{"issue":"12","key":"pone.0233084.ref023","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1086\/657321","article-title":"Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings","volume":"202","author":"L Bruni","year":"2010","journal-title":"J Infect Dis"},{"key":"pone.0233084.ref024","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pvr.2017.10.004","article-title":"Syndemic synergy of HPV and other sexually transmitted pathogens in the development of high-grade anal squamous intraepithelial lesions","volume":"4","author":"JC McCloskey","year":"2017","journal-title":"Papillomavirus Res"},{"issue":"4","key":"pone.0233084.ref025","first-page":"139","article-title":"Frequency of human papillomavirus infection and genotype distribution among women with known cytological diagnosis in a Southern Italian region","volume":"51","author":"M Chironna","year":"2010","journal-title":"J Prev Med Hyg"},{"issue":"10","key":"pone.0233084.ref026","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1600-0463.2011.02784.x","article-title":"High prevalence of human papillomavirus infection in Eastern European and West African women immigrants in South Italy","volume":"119","author":"ML Tornesello","year":"2011","journal-title":"APMIS"},{"issue":"1","key":"pone.0233084.ref027","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/adc.2003.047126","article-title":"Vaccination rates in a multicultural population","volume":"90","author":"MF van der Wal","year":"2005","journal-title":"Arch Dis Child"},{"issue":"33","key":"pone.0233084.ref028","doi-asserted-by":"crossref","first-page":"4149","DOI":"10.1016\/j.vaccine.2014.05.058","article-title":"Identifying human papillomavirus vaccination practices among primary care providers of minority, low-income and immigrant patient populations","volume":"32","author":"DM Bruno","year":"2014","journal-title":"Vaccine"},{"issue":"11","key":"pone.0233084.ref029","doi-asserted-by":"crossref","first-page":"e0187193","DOI":"10.1371\/journal.pone.0187193","article-title":"Catch-up HPV vaccination status of adolescents in relation to socioeconomic factors, individual beliefs and sexual behaviour","volume":"12","author":"M Grandahl","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"pone.0233084.ref030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/CEJ.0000000000000274","article-title":"Human papillomavirus immunization uptake among girls with a refugee background compared with Danish-born girls: a national register-based cohort study","volume":"27","author":"SP M\u00f8ller","year":"2018","journal-title":"Eur J Cancer Prev"},{"issue":"3\u20134","key":"pone.0233084.ref031","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ypmed.2012.01.013","article-title":"Inequalities in cervical cancer screening for women with or without a regular consulting in primary care for gynaecological health, in Paris, France","volume":"54","author":"F Grillo","year":"2012","journal-title":"Prev Med"},{"key":"pone.0233084.ref032","first-page":"45","article-title":"L\u2019absence de d\u00e9pistage du cancer du col de l\u2019ut\u00e9rus en fonction des caract\u00e9ristiques migratoires chez les femmes de l\u2019agglom\u00e9ration parisienne en 2010","volume":"2-3-4","author":"F Grillo","year":"2012","journal-title":"Bull Epidemiol Hebd"},{"key":"pone.0233084.ref033","first-page":"55","volume-title":"D\u00e9pistage et pr\u00e9vention du cancer du col de l\u2019ut\u00e9rus: actualisation du r\u00e9f\u00e9rentiel de pratiques de l\u2019examen p\u00e9riodique de sant\u00e9 (EPS)","author":"Haute Autorit\u00e9 de Sant\u00e9","year":"2013"},{"key":"pone.0233084.ref034","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. D\u00e9pistage \u00c9valuation de la recherche des papillomavirus humains (HPV) en d\u00e9pistage primaire des l\u00e9sions pr\u00e9canc\u00e9reuses et canc\u00e9reuses du col de l\u2019ut\u00e9rus et de la place du double immunomarquage p16\/Ki67. Synth\u00e8se et recommandations. P. 36. Saint-Denis La Plaine: Haute Autorit\u00e9 de Sant\u00e9 (HAS); juillet 2019. (Last accessed September 2019).: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2019-07\/synthese_et_recommandations_hpv.pdf. Accessed 23 August 2019."},{"issue":"4","key":"pone.0233084.ref035","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrc.2018.13","article-title":"Opportunities and challenges for human papillomavirus vaccination in cancer","volume":"18","author":"RBS Roden","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"pone.0233084.ref036","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1128\/JCM.34.12.3056-3062.1996","article-title":"Cervical mucus antibodies against human papillomavirus type 16, 18, and 33 capsids in relation to presence of viral DNA","volume":"34","author":"Z Wang","year":"1996","journal-title":"J Clin Microbiol"},{"issue":"3","key":"pone.0233084.ref037","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/ijc.10939","article-title":"Mucosal immunoglobulin-A and -G responses to oncogenic human papilloma virus capsids","volume":"104","author":"T Sasagawa","year":"2003","journal-title":"Int J Cancer"},{"issue":"Pt 4","key":"pone.0233084.ref038","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1099\/vir.0.83458-0","article-title":"Association of serum and mucosal neutralizing antibodies to human papillomavirus type 16 (HPV-16) with HPV-16 infection and cervical disease","volume":"89","author":"ZZ Mbulawa","year":"2008","journal-title":"J Gen Virol"},{"issue":"1","key":"pone.0233084.ref039","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jmv.2014","article-title":"Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia","volume":"65","author":"DJ Marais","year":"2001","journal-title":"J Med Virol"},{"issue":"3","key":"pone.0233084.ref040","first-page":"625","article-title":"Immunologic responses to human papillomavirus infection","volume":"23","author":"L Gissmann","year":"1996","journal-title":"Obstet Gynecol Clin North Am"},{"key":"pone.0233084.ref041","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0738-081X(96)00166-6","article-title":"Humoral immune response to human papillomavirus infection","volume":"15","author":"JJ Carter","year":"1997","journal-title":"Clin. Dermatol"},{"issue":"6","key":"pone.0233084.ref042","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"JJ Carter","year":"2000","journal-title":"J Infect Dis"},{"issue":"12","key":"pone.0233084.ref043","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1128\/JCM.39.12.4344-4348.2001","article-title":"Prevalence of anti-human papillomavirus type 16, 18, 31, and 58 virus-like particles in women in the general population and in prostitutes","volume":"39","author":"A Touz\u00e9","year":"2001","journal-title":"J Clin Microbiol"},{"key":"pone.0233084.ref044","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-9378-5-19","article-title":"HPV\u2014immune response to infection and vaccination","volume":"5","author":"M Stanley","year":"2010","journal-title":"Infect Agent Cancer"},{"issue":"9","key":"pone.0233084.ref045","doi-asserted-by":"crossref","first-page":"e74797","DOI":"10.1371\/journal.pone.0074797","article-title":"Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses","volume":"8","author":"M Scherpenisse","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"pone.0233084.ref046","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1086\/315364","article-title":"Detection of cervical antibodies to human papillomavirus type 16 (HPV-16) capsid antigens in relation to detection of HPV-16 DNA and cervical lesions","volume":"181","author":"ME Hagensee","year":"2000","journal-title":"J Infect Dis"},{"issue":"3","key":"pone.0233084.ref047","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/infdis\/172.3.691","article-title":"Cervicovaginal overproduction of specific IgG to human immunodeficiency virus (HIV) contrasts with normal or impaired IgA local response in HIV infection","volume":"172","author":"L B\u00e9lec","year":"1995","journal-title":"J Infect Dis"},{"issue":"4","key":"pone.0233084.ref048","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/(SICI)1097-0215(19980209)75:4<529::AID-IJC7>3.0.CO;2-V","article-title":"Immunoglobulin-A and -G responses against virus-like particles (VLP) of human papillomavirus type 16 in women with cervical cancer and cervical intra-epithelial lesions","volume":"75","author":"T Sasagawa","year":"1998","journal-title":"Int J Cancer"},{"issue":"Pt 3","key":"pone.0233084.ref049","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1099\/0022-1317-81-3-701","article-title":"Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11, 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women","volume":"81","author":"A Petter","year":"2000","journal-title":"J Gen Virol"},{"key":"pone.0233084.ref050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/scbi.1999.0146","article-title":"The serological response to papillomaviruses","volume":"9","author":"J Dillner","year":"1999","journal-title":"Semin. Cancer Biol"},{"issue":"Pt 2","key":"pone.0233084.ref051","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1099\/0022-1317-80-2-409","article-title":"Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16","volume":"80","author":"HJ Bontkes","year":"1999","journal-title":"J Gen Virol"},{"key":"pone.0233084.ref052","unstructured":"Institut National de la Statistique et des Etudes Economiques (INSEE.2015). Population \u00e9trang\u00e8re par sexe et \u00e2ge en 2012. (Last accessed September 2019). http:\/\/www.insee.fr\/fr\/themes\/tableau.asp?reg_id=0&ref_id=NATTEF02162"},{"issue":"1","key":"pone.0233084.ref053","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1128\/CDLI.2.1.57-61.1995","article-title":"Dilution assessment of cervicovaginal secretions obtained by vaginal washing for immunological assays","volume":"2","author":"L B\u00e9lec","year":"1995","journal-title":"Clin Diagn Lab Immunol"},{"issue":"16","key":"pone.0233084.ref054","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","article-title":"The 2001 Bethesda System: terminology for reporting results of cervical cytology","volume":"287","author":"D Solomon","year":"2002","journal-title":"JAMA"},{"issue":"6","key":"pone.0233084.ref055","doi-asserted-by":"crossref","first-page":"e0217486","DOI":"10.1371\/journal.pone.0217486","article-title":"High prevalence of cervical high-risk human papillomavirus infection mostly covered by Gardasil-9 prophylactic vaccine in adult women living in N\u2019Djamena, Chad","volume":"14","author":"RS Mboumba Bouassa","year":"2019","journal-title":"PLoS One"},{"key":"pone.0233084.ref056","article-title":"Production of papillomavirus-based gene transfer vectors","volume":"Chapter 26","author":"CB Buck","year":"2007","journal-title":"Curr Protoc Cell Biol"},{"issue":"7","key":"pone.0233084.ref057","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1371\/journal.ppat.0020069","article-title":"Carrageenan is a potent inhibitor of papillomavirus infection","volume":"2","author":"CB Buck","year":"2006","journal-title":"PLoS Pathog"},{"issue":"7","key":"pone.0233084.ref058","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nm1598","article-title":"Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan","volume":"13","author":"JN Roberts","year":"2007","journal-title":"Nat Med"},{"issue":"2","key":"pone.0233084.ref059","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.virol.2006.08.037","article-title":"Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region","volume":"358","author":"K Kondo","year":"2007","journal-title":"Virology"},{"issue":"5","key":"pone.0233084.ref060","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/jmv.21124","article-title":"Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes","volume":"80","author":"K Kondo","year":"2008","journal-title":"J Med Virol"},{"issue":"47","key":"pone.0233084.ref061","doi-asserted-by":"crossref","first-page":"8585","DOI":"10.1016\/j.vaccine.2011.09.021","article-title":"Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera","volume":"29","author":"E Draper","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"pone.0233084.ref062","doi-asserted-by":"crossref","first-page":"e97232","DOI":"10.1371\/journal.pone.0097232","article-title":"Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types","volume":"9","author":"K Kwak","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"pone.0233084.ref063","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.vaccine.2011.10.096","article-title":"International collaborative proficiency study of Human Papillomavirus type 16 serology","volume":"30","author":"C Eklund","year":"2012","journal-title":"Vaccine"},{"issue":"6","key":"pone.0233084.ref064","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/infdis\/jiy252","article-title":"Human Papillomavirus Serology Among Women Living With HIV: Type-Specific Seroprevalence, Seroconversion, and Risk of Cervical Reinfection","volume":"218","author":"H Kelly","year":"2018","journal-title":"J Infect Dis"},{"key":"pone.0233084.ref065","unstructured":"Bruni L, Albero G, Serrano B, Mena M, G\u00f3mez D, Mu\u00f1oz J, et al. Human Papillomavirus and Related Diseases in France. Summary Report 10 December 2018. (Last accessed September 2019). http:\/\/www.hpvcentre.net\/statistics\/reports\/FRA.pdf"},{"issue":"1","key":"pone.0233084.ref066","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/1471-0528.12015","article-title":"Characteristics of HPV infection over time in European women who are HIV-1 positive","volume":"120","author":"MACH-1 Study Group","year":"2013","journal-title":"BJOG"},{"issue":"10","key":"pone.0233084.ref067","first-page":"1559","article-title":"High Prevalence of Anal Human Papillomavirus-Associated Cancer Precursors in a Contemporary Cohort of Asymptomatic HIV-Infected Women","volume":"60","author":"I Heard","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"11","key":"pone.0233084.ref068","doi-asserted-by":"crossref","first-page":"e79372","DOI":"10.1371\/journal.pone.0079372","article-title":"Human papillomavirus types distribution in organised cervical cancer screening in France","volume":"8","author":"I Heard","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"pone.0233084.ref069","doi-asserted-by":"crossref","first-page":"e0122488","DOI":"10.1371\/journal.pone.0122488","article-title":"Prevalence of human papillomavirus genotypes among African women with normal cervical cytology and neoplasia: a systematic review and meta-analysis","volume":"10","author":"RK Ogembo","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"pone.0233084.ref070","doi-asserted-by":"crossref","first-page":"e0170189","DOI":"10.1371\/journal.pone.0170189","article-title":"Prevalence of and Associated Risk Factors for High Risk Human Papillomavirus among Sexually Active Women, Swaziland","volume":"12","author":"TG Ginindza","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"pone.0233084.ref071","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/QAD.0000000000001301","article-title":"Epidemiology of high-risk human papillomavirus and cervical lesions in African women living with HIV\/AIDS: effect of anti-retroviral therapy","volume":"31","author":"HA Kelly","year":"2017","journal-title":"AIDS"},{"issue":"9","key":"pone.0233084.ref072","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/infdis\/jiv753","article-title":"Natural Acquired Immunity Against Subsequent Genital Human Papillomavirus Infection: A Systematic Review and Meta-analysis","volume":"213","author":"DC Beachler","year":"2016","journal-title":"J Infect Dis"},{"key":"pone.0233084.ref073","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1186\/1471-2334-14-361","article-title":"prevalence and persistence of high-risk human papillomavirus infection among women in Santiago, Chile","volume":"14","author":"FA Castro","year":"2014","journal-title":"BMC Infect Dis"},{"key":"pone.0233084.ref074","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1186\/s12879-014-0578-0","article-title":"Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study","volume":"14","author":"PS de Araujo-Souza","year":"2014","journal-title":"BMC Infect Dis"},{"issue":"7","key":"pone.0233084.ref075","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.bjc.6601272","article-title":"Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica","volume":"89","author":"SS Wang","year":"2003","journal-title":"Br J Cancer"},{"issue":"12","key":"pone.0233084.ref076","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.4161\/hv.6.12.13399","article-title":"Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16\/18 AS04-adjuvanted vaccine","volume":"6","author":"TF Schwarz","year":"2010","journal-title":"Hum Vaccin"},{"issue":"2","key":"pone.0233084.ref077","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4161\/hv.22693","article-title":"Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination","volume":"9","author":"M Scherpenisse","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"pone.0233084.ref078","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/08828240152716655","article-title":"Antibodies against human papillomavirus type 16 and 18 E6 and E7 proteins in cervicovaginal washings and serum of patients with cervical neoplasia","volume":"14","author":"MY Tjiong","year":"2001","journal-title":"Viral Immunol"},{"issue":"9","key":"pone.0233084.ref079","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/jmv.20901","article-title":"Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia","volume":"79","author":"JA Passmore","year":"2007","journal-title":"J Med Virol"},{"issue":"3 Suppl 1","key":"pone.0233084.ref080","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/j.ygyno.2005.07.100","article-title":"Correlates of cervical mucosal antibodies to human papillomavirus 16: results from a case control study","volume":"99","author":"C Bierl","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"5","key":"pone.0233084.ref081","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1600-0897.2005.00267.x","article-title":"Immunologic uniqueness of the genital tract: challenge for vaccine development","volume":"53","author":"J Mestecky","year":"2005","journal-title":"Am J Reprod Immunol"},{"issue":"3","key":"pone.0233084.ref082","first-page":"266","article-title":"Immune responses to human papilloma viruses","volume":"130","author":"M Stanley","year":"2009","journal-title":"Indian J Med Res"},{"issue":"2","key":"pone.0233084.ref083","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1365-2249.2007.03384.x","article-title":"Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination","volume":"148","author":"J Dillner","year":"2007","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"pone.0233084.ref084","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/vim.2009.0055","article-title":"Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV","volume":"22","author":"ZA Malik","year":"2009","journal-title":"Viral Immunol"},{"issue":"21","key":"pone.0233084.ref085","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1093\/jnci\/djq384","article-title":"Epidemiological study of anti-HPV16\/18 seropositivity and subsequent risk of HPV16 and -18 infections","volume":"102","author":"M Safaeian","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"pone.0233084.ref086","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/infdis\/jiu139","article-title":"Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16\/18 antibodies: analysis of the control arm of PATRICIA","volume":"210","author":"X Castellsagu\u00e9","year":"2014","journal-title":"J Infect Dis"},{"issue":"1","key":"pone.0233084.ref087","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/infdis\/jiy112","article-title":"Risk of HPV-16\/18 Infections and Associated Cervical Abnormalities in Women Seropositive for Naturally Acquired Antibodies: Pooled Analysis Based on Control Arms of Two Large Clinical Trials","volume":"218","author":"M Safaeian","year":"2018","journal-title":"J Infect Dis"},{"issue":"7","key":"pone.0233084.ref088","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"A Hildesheim","year":"2007","journal-title":"JAMA"},{"issue":"5","key":"pone.0233084.ref089","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00365540903501608","article-title":"Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes","volume":"42","author":"J Palmroth","year":"2010","journal-title":"Scand J Infect Dis"},{"issue":"3","key":"pone.0233084.ref090","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up","volume":"8","author":"CM Roteli-Martins","year":"2012","journal-title":"Hum Vaccin Immunother"},{"issue":"10","key":"pone.0233084.ref091","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"SE Olsson","year":"2009","journal-title":"Hum Vaccin"},{"issue":"1","key":"pone.0233084.ref092","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/bjc.2011.185","article-title":"End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24\u201345 years of age","volume":"105","author":"X Castellsagu\u00e9","year":"2011","journal-title":"Br J Cancer"},{"issue":"13","key":"pone.0233084.ref093","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.vaccine.2016.02.019","article-title":"Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines","volume":"34","author":"H Faust","year":"2016","journal-title":"Vaccine"},{"key":"pone.0233084.ref094","doi-asserted-by":"crossref","first-page":"100174","DOI":"10.1016\/j.pvr.2019.100174","article-title":"HPV vaccination in HIV infection","volume":"8","author":"CJ Lacey","year":"2019","journal-title":"Papillomavirus Res"},{"issue":"15","key":"pone.0233084.ref095","first-page":"118","volume":"84","author":"World Health Organization","year":"2009","journal-title":"Human papillomavirus vaccines. WHO position paper. Releve epidemiologique hebdomadaire \/ Section d\u2019hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record \/ Health Section of the Secretariat of the League of Nations"},{"key":"pone.0233084.ref096","unstructured":"World Health Organization. 2013 World health organization. Global action plan for the prevention and control of noncommunicable diseases 2013\u20132030. 2013. (Last accessed September 2019). http:\/\/apps.who.int\/iris\/bitstream\/10665\/94384\/1\/9789241506236_eng.pdf?ua=1"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0233084","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,18]],"date-time":"2020-05-18T17:52:08Z","timestamp":1589824328000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0233084"}},"subtitle":[],"editor":[{"given":"Craig","family":"Meyers","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,18]]},"references-count":96,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0233084","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,18]]}}}